U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H19BrN2.C4H4O4
Molecular Weight 435.312
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DEXBROMPHENIRAMINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=NC=CC=C2

InChI

InChIKey=SRGKFVAASLQVBO-DASCVMRKSA-N
InChI=1S/C16H19BrN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C16H19BrN2
Molecular Weight 319.239
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PANATUSS PEDIATRIC DROPS DXP
Palliative
PANATUSS PEDIATRIC DROPS DXP

Cmax

ValueDoseCo-administeredAnalytePopulation
27.98 ng/mL
6 mg 2 times / day steady-state, oral
DEXBROMPHENIRAMINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
234.2 ng × h/mL
6 mg 2 times / day steady-state, oral
DEXBROMPHENIRAMINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
22 h
6 mg 2 times / day steady-state, oral
DEXBROMPHENIRAMINE plasma
Homo sapiens

Doses

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Children 6 years of age to under 12 years; 2 mL every 4 - 6 hours.
Route of Administration: Oral
Substance Class Chemical
Record UNII
BPA9UT29BS
Record Status Validated (UNII)
Record Version